Updated on 8 February 2013
RegeneRx gets Notice of Allowance from Chinese Patent Office
Singapore: RegeneRx Biopharmaceuticals has received a Notice of Allowance of a Chinese patent application for uses of Thymosin beta 4 (TB4) for treating, preventing, inhibiting or reducing heart tissue deterioration, injury or damage in a subject with heart failure disease.
RegeneRx Biopharmaceuticals' claims also include uses for restoring heart tissue in those subjects. The patent will expire July 26, 2026.
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
